Balyasny Asset Management
KZR

Balyasny Asset Management’s Kezar Life Sciences KZR Stock Holding History

Balyasny Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,983
Closed -$280K – 2924
2022
Q4 		$280K Buy
3,983
+2,358
+145% +$175K ﹤0.01% 2019
2022
Q3 		$140K Sell
1,625
-1,375
-46% -$134K ﹤0.01% 2368
2022
Q2 		$248K Buy
+3,000
New +$265K ﹤0.01% 2155

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Balyasny Asset Management's KZR Position: Q1 2023 in Review

Balyasny Asset Management sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 3,983 shares — an estimated $280K sold.

Balyasny Asset Management first reported a position in KZR in Q2 2022 and held it in 3 quarters. The position peaked at $280K in Q4 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Balyasny Asset Management reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 3,983 Kezar Life Sciences shares in Q1 2023, an estimated $280K.
  • Balyasny Asset Management first reported a position in Kezar Life Sciences in Q2 2022 and held it in 3 quarters.
  • Balyasny Asset Management's Kezar Life Sciences position peaked at $280K in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.